Reduction of motoric agitation and restlessness by AF102B and tacrine in the macaque

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 11, Issue 1, 1999, Pages 79-85

  Fitten, L Jaime ^a   Ortiz, Freddy ^a   Siembieda, Douglas W ^a   O'Neill, Joseph ^a   Halgren, Eric ^a   Fisher, Abraham ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEVIMELINE; TACRINE;

AGITATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; CONTROLLED STUDY; FEMALE; INTRAMUSCULAR DRUG ADMINISTRATION; MACACA; MALE; MOTOR ACTIVITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RESTLESSNESS; VIDEOTAPE;

EID: 0032909407     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.11.1.79     Document Type: Article

References (49)

1. Cohen-Mansfield J, Werner P, Watson V, et al: Agitation among elderly persons at adult day-care centers: the experiences of relatives and staff members. Int Psychogeriatr 1995; 7:447-458
2. Gerdner LA, Buckwalter KC: A nursing challenge: assessment and management of agitation in Alzheimer's patients. J Gerontol Nursing 1994; 20:11-20
3. Mega MS, Cummings JL, Fiorello T, et al: The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996; 46:130-135
4. Stewart JT: Management of behavior problems in the demented patient. American Family Physician 1995; 52:2311-2317
5. Zayas EM, Grossberg GT: Treating the agitated Alzheimer patient. J Clin Psychiatry 1996; 57(suppl 7):46-51
6. Friedman R, Gryfe CI, Tal DT, et al: The noisy elderly patient: prevalence, assessment, and response to the antidepressant doxepin. J Geriatr Psychiatry Neurol 1992; 5:187-191
7. Kunik ME, Yudofsky SC, Silver JM, et al: Pharmacologic approach to management of agitation associated with dementia. J Clin Psychiatry 1994; 55:13S-17S
8. Lemke MR: Effect of carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics. J Clin Psychiatry 1995; 56:354-357
9. Devanand DP, Levy SR: Neuroleptic treatment of agitation and psychosis in dementia. J Geriatr Psychiatry Neurol 1995; 1(8 suppl):S18-S27
10. Schneider LS, Sobin PB: Non-neuroleptic treatment of behavioral symptoms and agitation in Alzheimer's disease and other dementia. Psychopharmacol Bull 1992; 28:71-79
11. Sunderland T: Treatment of the elderly suffering from psychosis and dementia. J Clin Psychiatry 1996; 9(57 suppl):53-56
12. Shankle WR, Nielson KA, Cotman CW: Low-dose propranolol reduces aggression and agitation resembling that associated with orbitofrontal dysfunction in elderly demented patients. Alzheimer Dis Assoc Disord 1995; 9:233-237
13. Cummings JL, Kaufer D: Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology 1996; 47:876-683
14. Bartus RT, Reginald LD, Pontecorvo MJ, et al: The cholinergic hypothesis: a historical overview, current perspective and future directions, in Memory Dysfunctions: An Integration of Animal and Human Research From Preclinical and Clinical Perspectives, edited by Olton DS, Gamzu E, Corkin S. New York, New York Academy of Sciences, 1985, pp 332-358
15. Perry EK: The cholinergic hypothesis: ten years on. Br Med Bull 1986; 42:63-65
16. Fitten LJ, O'Neill J, Siembieda DW, et al: Reduction of motoric agitation and restlessness by AF102B and tacrine in the macaque. Presented at the Fourth International Conference for Progress in Alzheimer's and Parkinson's Diseases, Tel Aviv, Israel, May 14-17, 1997
17. Hornykiewics O: Metabolism of brain dopamine in human parkinsonism: neurochemical and clinical aspects, in Biochemistry and Pharmacology of the Basal Ganglia, edited by Costa E, Cote L, Yahr M. New York, Raven, 1966, pp 171-185
18. Kopin I: Neurotransmitters and disorders of the basal ganglia, in Basic Biochemistry, edited by Siegel A, Agranoff AB, Molinoff PB. New York, Raven, 1994, pp 899-918
19. De Long M: Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990; 13:281-285
20. Bartus RT, Dean RL: Tetrahydroaminoacridine, 3,4-diaminopyridine and physostigmine: direct comparison of effects on memory in aged primates. Neurobiol Aging 1988; 9:351-356
21. Fitten LJ, Perryman KM, Tachiki K, et al: Oral tacrine administration in middle-aged monkeys: effects on discrimination learning. Neurobiol Aging 1988; 9:221-224
22. Rupniak NMJ, Field MJ, Samson NA, et al: Direct comparison of cognitive facilitation by physostigmine and tetrahydroaminoacridine in two primate models. Neurobiol Aging 1990; 11:609-613
23. Shaw FH, Bently GA: The pharmacology of some new anticholinesterases. Australian Journal of Experimental Biology and Medical Science 1953; 31:573-576
24. Fisher A, Karton Y, Heldman E, et al: Progress in medicinal chemistry of novel selective muscarinic agonists. Drug Des Discov 1993; 9:221-235
25. Fisher A, Brandeis R, Karton Y, et al: ±-cis-2-methyl-spiro(1,3-oxathiolane-5,3′)quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease. J Pharmacol Exp Ther 1991; 257:392-403
26. Fisher A, Barak D: Progress and perspectives in new muscarinic agonists. Drug News and Perspectives 1994; 7:453-464
27. Fisher A, Heldman E, Gurwitz D, et al: M1 agonists for the treatment of Alzheimer's disease: novel properties and clinical update. Ann NY Acad Sci 1996; 777:189-196
28. Davis KL, Thai LJ, Gamzu ER, et al: A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease: Tacrine Collaborative Study Group. N Engl J Med 1992; 327:1253-1259
29. Eagger SA, Levy R, Sahakian BJ: Tacrine in Alzheimer's disease. Lancet 1991; 338:50-51
30. Farlow M, Gracon SI, Hershey LA, et al: A controlled trial of tacrine in Alzheimer's disease: the Tacrine Study Group. JAMA 1992; 268:2523-2529
31. Fitten LJ, Perryman KM, Gross PL: Treatment of Alzheimer's disease with short and long-term oral THA and lecithin: a double blind study. Am J Psychiatry 1990; 147:239-242
32. Perryman KM, Fitten LJ: Delayed matching-to-sample performance during a double blind trial of tacrine (THA) and lecithin in patients with Alzheimer's disease. Life Sci 1993; 53:479-486
33. Fitten LJ, Flood JF, Baxter CF: Long-term oral administration of memory enhancing doses of tacrine in mice: a study of potential toxicity and side effects. J Gerontol 1987; 42:681-685
34. Dawson GR, Iversen SD: The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory. Behav Brain Res 1993; 57:143-153
35. Fisher A, Brandeis R, Karton Y, et al: AF102B: rational treatment strategy for Alzheimer's disease: recent advances. Adv Neurol 1990; 51:257-259
36. Sadot E, Gurwitz D, Barg J, et al: Activation of M1 muscarinic acetylcholine receptor regulates τ phosphorylation in transfected PC12 cells. J Neurochem 1996; 66:877-880
37. Fisher A, Heldman E, Haring R, et al: New M1 agonists: from replacement treatment to delaying the progression of Alzheimer's disease: novel properties. Life Sciences Research 1995; 972:13-35
38. Buccafusco JJ, Jackson WJ: Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in the young and aged monkeys. Neurobiol Aging 1991; 12:233-238
39. Jackson WJ, Elrod K, Buccafusco JJ: Delayed matching-to-sample in monkeys as a model for learning and memory deficits: role of brain nicotinic receptors, in Novel Approaches to the Treatment of Alzheimer's Disease, edited by Meyer EM, Simpkins JW. New York, Plenum, 1989, pp 39-52
40. Uno H: Age-related pathology and biosenescent markers in captive rhesus macaques. Age 1997; 20:1-13
41. O'Neill J, Fitten LJ, Siembieda D, et al: Effects of AF102B and THA on delayed match-to-sample in monkeys. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22:665-678
42. Fitten LJ, O'Neill J, Siembieda D, et al: Selective attention-enhancing effects of AF102B and THA in young and mid-aged monkeys. Society for Neuroscience Abstracts 1995; 21:167
43. Siembieda D, Fitten LJ, O'Neill J, et al: Memory-enhancing effects of AF102B and THA in monkeys. Society for Neuroscience Abstracts 1995; 21:167
44. Physicians' Desk Reference, 49th edition. Oradell, NJ, Medical Economics Data, 1995
45. Faber R: Neuropsychiatric assessment, in Textbook of Geriatric Neuropsychiatry, edited by Coffey CE, Cummings JL. Washington, DC, American Psychiatric Press, 1994, pp 99-110
46. Sachdev P, Kruk J: Restlessness: the anatomy of a neuropsychiatric symptom. Aust NZ J Psychiatry 1996; 30:38-53
47. Woolf NJ: Cholinergic systems in mammalian brain and spinal cord. Prog Neurobiol 1991; 37:475-524
48. Jackson WJ, Buccafusco JJ, Terry AV, et al: Velnacrine maleate improves delayed matching performance by aged monkeys. Psychopharmacology 1995; 119:391-398
49. Fitten LJ, Perryman KM, O'Neill J, et al: Influence of cholinesterase inhibitors on cortical slow-wave activity in aging non-human primates. Pharmacol Biochem Behav 1994; 49:235-239